266 related articles for article (PubMed ID: 29932239)
1. Efficacy of different drugs in the treatment of minimal hepatic encephalopathy: A network meta-analysis involving 826 patients based on 10 randomized controlled trials.
Cai XJ; Wang L; Hu CM
J Cell Biochem; 2018 Nov; 119(10):8336-8345. PubMed ID: 29932239
[TBL] [Abstract][Full Text] [Related]
2. A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy.
Mittal VV; Sharma BC; Sharma P; Sarin SK
Eur J Gastroenterol Hepatol; 2011 Aug; 23(8):725-32. PubMed ID: 21646910
[TBL] [Abstract][Full Text] [Related]
3. Comparative Efficacy of Treatment Options for Minimal Hepatic Encephalopathy: A Systematic Review and Network Meta-Analysis.
Dhiman RK; Thumburu KK; Verma N; Chopra M; Rathi S; Dutta U; Singal AK; Taneja S; Duseja A; Singh M
Clin Gastroenterol Hepatol; 2020 Apr; 18(4):800-812.e25. PubMed ID: 31476436
[TBL] [Abstract][Full Text] [Related]
4. Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial.
Sharma K; Pant S; Misra S; Dwivedi M; Misra A; Narang S; Tewari R; Bhadoria AS
Saudi J Gastroenterol; 2014; 20(4):225-32. PubMed ID: 25038208
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of L-ornithine L-aspartate for minimal hepatic encephalopathy in patients with cirrhosis: A meta-analysis of randomized controlled trials.
He Q; Mao C; Chen Z; Zeng Y; Deng Y; Hu R
Arab J Gastroenterol; 2024 May; 25(2):84-92. PubMed ID: 38403493
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of probiotics in the treatment of minimal hepatic encephalopathy: A systematic review and meta-analysis.
Wibawa IDN; Mariadi IK; Shalim CP; Sindhughosa DA
Clin Exp Hepatol; 2023 Jun; 9(2):146-153. PubMed ID: 37502435
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy and safety of lactulose for minimal hepatic encephalopathy: a meta-analysis.
Luo M; Li L; Lu CZ; Cao WK
Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1250-7. PubMed ID: 21971378
[TBL] [Abstract][Full Text] [Related]
8. An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy.
Sharma P; Sharma BC; Puri V; Sarin SK
Eur J Gastroenterol Hepatol; 2008 Jun; 20(6):506-11. PubMed ID: 18467909
[TBL] [Abstract][Full Text] [Related]
9. l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials.
Bai M; Yang Z; Qi X; Fan D; Han G
J Gastroenterol Hepatol; 2013 May; 28(5):783-92. PubMed ID: 23425108
[TBL] [Abstract][Full Text] [Related]
10. L-Ornithine L-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses.
Butterworth RF; McPhail MJW
Drugs; 2019 Feb; 79(Suppl 1):31-37. PubMed ID: 30706425
[TBL] [Abstract][Full Text] [Related]
11. Effect of probiotic treatment on cirrhotic patients with minimal hepatic encephalopathy: A meta-analysis.
Cao Q; Yu CB; Yang SG; Cao HC; Chen P; Deng M; Li LJ
Hepatobiliary Pancreat Dis Int; 2018 Feb; 17(1):9-16. PubMed ID: 29428113
[TBL] [Abstract][Full Text] [Related]
12. Probiotics for patients with hepatic encephalopathy.
McGee RG; Bakens A; Wiley K; Riordan SM; Webster AC
Cochrane Database Syst Rev; 2011 Nov; (11):CD008716. PubMed ID: 22071855
[TBL] [Abstract][Full Text] [Related]
13. Acetyl-L-carnitine treatment in minimal hepatic encephalopathy.
Malaguarnera M; Gargante MP; Cristaldi E; Vacante M; Risino C; Cammalleri L; Pennisi G; Rampello L
Dig Dis Sci; 2008 Nov; 53(11):3018-25. PubMed ID: 18357530
[TBL] [Abstract][Full Text] [Related]
14. Rifaximin vs. lactulose in treatment of minimal hepatic encephalopathy.
Sidhu SS; Goyal O; Parker RA; Kishore H; Sood A
Liver Int; 2016 Mar; 36(3):378-85. PubMed ID: 26201713
[TBL] [Abstract][Full Text] [Related]
15. [Prevention and treatment of hepatic encephalopathy].
Sivolap YP
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10):144-147. PubMed ID: 29171503
[TBL] [Abstract][Full Text] [Related]
16. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
[TBL] [Abstract][Full Text] [Related]
17. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy.
Agrawal A; Sharma BC; Sharma P; Sarin SK
Am J Gastroenterol; 2012 Jul; 107(7):1043-50. PubMed ID: 22710579
[TBL] [Abstract][Full Text] [Related]
18. Predictors of nonresponse to lactulose for minimal hepatic encephalopathy in patients with cirrhosis.
Sharma P; Sharma BC; Sarin SK
Liver Int; 2009 Oct; 29(9):1365-71. PubMed ID: 19555401
[TBL] [Abstract][Full Text] [Related]
19. Probiotics are helpful in hepatic encephalopathy: a meta-analysis of randomized trials.
Saab S; Suraweera D; Au J; Saab EG; Alper TS; Tong MJ
Liver Int; 2016 Jul; 36(7):986-93. PubMed ID: 26561214
[TBL] [Abstract][Full Text] [Related]
20. Systematic review with network meta-analysis: the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy.
Zhu GQ; Shi KQ; Huang S; Wang LR; Lin YQ; Huang GQ; Chen YP; Braddock M; Zheng MH
Aliment Pharmacol Ther; 2015 Apr; 41(7):624-35. PubMed ID: 25684317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
